Drug Trial Radar · NCT00418522
This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
413
Actual
Start
Mar 2007
Primary completion
Aug 2008
Study completion Aug 2008
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 5, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to determine if inhaled insulin is effective in treating type 2 diabetes mellitus.
Conditions
- Diabetes Mellitus, Type 2
Interventions
Insulin glargineDrug
Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
Inhaled Insulin (Exubera)Drug
Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) PopulationTime frame: Baseline, Week 26
Locations
73 sites in 2 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Tucson, Arizona
Pfizer Investigational Site
Concord, California
Pfizer Investigational Site
Encino, California
Pfizer Investigational Site
Fresno, California
Pfizer Investigational Site
Fullerton, California
Pfizer Investigational Site
Long Beach, California
Pfizer Investigational Site
Mission Viejo, California
Pfizer Investigational Site
Pasadena, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
San Luis Obispo, California
Pfizer Investigational Site
Spring Valley, California
Pfizer Investigational Site
Stockton, California
Pfizer Investigational Site
Walnut Creek, California
Pfizer Investigational Site
West Hills, California
Pfizer Investigational Site
Golden, Colorado
Pfizer Investigational Site
Waterbury, Connecticut
Pfizer Investigational Site
Newark, Delaware
Pfizer Investigational Site
Chiefland, Florida
Pfizer Investigational Site
Clearwater, Florida
Pfizer Investigational Site
Hollywood, Florida
Pfizer Investigational Site
Kissimmee, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Ocala, Florida
Pfizer Investigational Site
Saint Cloud, Florida
Pfizer Investigational Site
Winter Park, Florida
Pfizer Investigational Site
Atlanta, Georgia
Pfizer Investigational Site
Lawrenceville, Georgia
Pfizer Investigational Site
Lawrenceville, Georgia
Pfizer Investigational Site
Woodstock, Georgia
Pfizer Investigational Site
Boise, Idaho
Pfizer Investigational Site
Hayden Lake, Idaho
Pfizer Investigational Site
Indianapolis, Indiana
Pfizer Investigational Site
Overland Park, Kansas
Pfizer Investigational Site
Topeka, Kansas
Pfizer Investigational Site
Lexington, Kentucky
Pfizer Investigational Site
Louisville, Kentucky
Pfizer Investigational Site
Baton Rouge, Louisiana
Pfizer Investigational Site
New Orleans, Louisiana
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.